KR102352847B1 - 염증성 장 질환을 위한 바이오마커 - Google Patents

염증성 장 질환을 위한 바이오마커 Download PDF

Info

Publication number
KR102352847B1
KR102352847B1 KR1020197002309A KR20197002309A KR102352847B1 KR 102352847 B1 KR102352847 B1 KR 102352847B1 KR 1020197002309 A KR1020197002309 A KR 1020197002309A KR 20197002309 A KR20197002309 A KR 20197002309A KR 102352847 B1 KR102352847 B1 KR 102352847B1
Authority
KR
South Korea
Prior art keywords
genes
ibd
risk
disease
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197002309A
Other languages
English (en)
Korean (ko)
Other versions
KR20190025637A (ko
Inventor
폴 에이. 라이언스
오언 에프. 맥킨니
다니엘레 비아스키
제임스 리
Original Assignee
캠브리지 엔터프라이즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캠브리지 엔터프라이즈 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20190025637A publication Critical patent/KR20190025637A/ko
Application granted granted Critical
Publication of KR102352847B1 publication Critical patent/KR102352847B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020197002309A 2016-07-05 2017-07-05 염증성 장 질환을 위한 바이오마커 Expired - Fee Related KR102352847B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1611738.4A GB201611738D0 (en) 2016-07-05 2016-07-05 Biomarkers for inflammatory bowel disease
GB1611738.4 2016-07-05
PCT/IB2017/000997 WO2018007872A1 (en) 2016-07-05 2017-07-05 Biomarkers for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
KR20190025637A KR20190025637A (ko) 2019-03-11
KR102352847B1 true KR102352847B1 (ko) 2022-01-17

Family

ID=56891052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002309A Expired - Fee Related KR102352847B1 (ko) 2016-07-05 2017-07-05 염증성 장 질환을 위한 바이오마커

Country Status (15)

Country Link
US (3) US11041206B2 (enExample)
EP (1) EP3481964B1 (enExample)
JP (2) JP7111630B2 (enExample)
KR (1) KR102352847B1 (enExample)
CN (1) CN109477145B (enExample)
AU (1) AU2017293417B2 (enExample)
CA (1) CA3029912A1 (enExample)
DK (1) DK3481964T3 (enExample)
ES (1) ES2906192T3 (enExample)
GB (1) GB201611738D0 (enExample)
HU (1) HUE058197T2 (enExample)
LT (1) LT3481964T (enExample)
PL (1) PL3481964T3 (enExample)
PT (1) PT3481964T (enExample)
WO (1) WO2018007872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10515408B2 (en) 2003-08-13 2019-12-24 Bgc Partners, Inc. Systems and methods for bid/offer liquidity spread trading
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3866920B1 (en) 2018-10-18 2025-12-10 T.J.Smith And Nephew, Limited Tissue treatment device
GB201817052D0 (en) 2018-10-19 2018-12-05 Smith & Nephew Tissue treatment device
CN110400603A (zh) * 2019-07-23 2019-11-01 中国石油大学(华东) 基于格局加权的ibd矩阵计算方法
GB201912518D0 (en) 2019-08-30 2019-10-16 Cambridge Entpr Ltd Inflammatory disease prognostics
GB202005867D0 (en) 2020-04-22 2020-06-03 Smith & Nephew Tissue treatment device
GB202100527D0 (en) 2021-01-15 2021-03-03 Smith & Nephew Systems and methods for managing operation of wound dressings or wound treatment devices
WO2022190036A2 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Methods for predicting treatment response in ulcerative colitis
CN114517228A (zh) * 2021-12-31 2022-05-20 青岛锐翌精准医学检验有限公司 炎症性肠病标志基因及其应用
CN114645088B (zh) * 2022-04-22 2023-12-15 广东省人民医院 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统
EP4606910A1 (en) * 2024-02-21 2025-08-27 Royal College of Surgeons in Ireland Diagnostic and prognostic methods relating to ulcerative colitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084312A1 (en) 2009-01-20 2010-07-29 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
WO2016066288A1 (en) 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412301D0 (en) 2004-06-02 2004-07-07 Diagenic As Product and method
EP1888789A2 (en) * 2005-06-06 2008-02-20 Wyeth a Corporation of the State of Delaware Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
GB0610949D0 (en) * 2006-06-02 2006-07-12 Glaxosmithkline Biolog Sa Method
MX2010005893A (es) * 2007-11-29 2011-03-04 Genentech Inc Star Marcadores de expresion genica para enfermedad inflamatoria de intestino.
US20100222262A1 (en) * 2008-04-02 2010-09-02 Metaproteomics, Llc Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
EP2419532A1 (en) * 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
CA2795776A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
KR20140097336A (ko) * 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
WO2013138497A1 (en) 2012-03-13 2013-09-19 Baylor Research Institute Early detection of tuberculosis treatment response
MX358730B (es) 2012-10-05 2018-09-03 Nestec Sa Metodos para predecir y monitorear cicatrizacion de la mucosa.
EP2931923A1 (en) 2012-12-13 2015-10-21 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
CN105683392A (zh) * 2013-03-15 2016-06-15 博德研究所 树突细胞应答基因表达、物质组合物及其使用方法
US10619210B2 (en) * 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
MA39804A (fr) * 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3262193A2 (en) * 2015-02-26 2018-01-03 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
JP2018512876A (ja) 2015-04-22 2018-05-24 ミナ セラピューティクス リミテッド ｓａＲＮＡ組成物および使用方法
US20170003277A1 (en) * 2015-07-01 2017-01-05 Michael Hayden Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084312A1 (en) 2009-01-20 2010-07-29 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
WO2016066288A1 (en) 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Current Gastroenterology Reports (2015) 17:26
European Journal of Clinical Investigation (1982) 12(4):351-359
Gastroenterology (2014) 146(5)S1:S-238*
The Journal of Clinical Investigation (2011) 121(10):4170-4179

Also Published As

Publication number Publication date
CN109477145A (zh) 2019-03-15
JP2019527039A (ja) 2019-09-26
GB201611738D0 (en) 2016-08-17
US20180010187A1 (en) 2018-01-11
AU2017293417A1 (en) 2019-02-21
US10202651B2 (en) 2019-02-12
US10640829B2 (en) 2020-05-05
NZ750396A (en) 2020-12-18
US20180010189A1 (en) 2018-01-11
PL3481964T3 (pl) 2022-04-11
JP2020198884A (ja) 2020-12-17
PT3481964T (pt) 2022-02-17
EP3481964B1 (en) 2021-12-29
WO2018007872A9 (en) 2018-03-15
JP7111630B2 (ja) 2022-08-02
US20190032140A1 (en) 2019-01-31
WO2018007872A1 (en) 2018-01-11
CA3029912A1 (en) 2018-01-11
DK3481964T3 (da) 2022-02-07
HUE058197T2 (hu) 2022-07-28
AU2017293417B2 (en) 2019-11-14
CN109477145B (zh) 2021-04-09
EP3481964A1 (en) 2019-05-15
US11041206B2 (en) 2021-06-22
LT3481964T (lt) 2022-04-11
ES2906192T3 (es) 2022-04-13
KR20190025637A (ko) 2019-03-11

Similar Documents

Publication Publication Date Title
KR102352847B1 (ko) 염증성 장 질환을 위한 바이오마커
Halloran et al. The transcripts associated with organ allograft rejection
US10260097B2 (en) Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US20160002732A1 (en) Molecular diagnostic test for cancer
AU2012261820A1 (en) Molecular diagnostic test for cancer
AU2016228508A1 (en) Methods for diagnosis of sepsis
US20240247315A1 (en) Diagnosing inflammatory bowel diseases
EP3146076A2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
EP2603604B1 (en) Method and kit for the diagnosis and/or prognosis of tolerance in liver transplantation
AU2021221905B2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
HK40007518B (en) Biomarkers for inflammatory bowel disease
NZ750396B2 (en) Biomarkers for inflammatory bowel disease
HK40003433B (en) Biomarkers for inflammatory bowel disease
HK40003433A (en) Biomarkers for inflammatory bowel disease
AU2024218990A1 (en) Method for identifying kidney allograft rejection genes in urine and utility of making those measurements

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250114

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250114